Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results.
Thirty-two patients with laparoscopic diagnosis of endometriosis were treated for 6 months with the gonadotropin-releasing hormone agonist goserelin depot. Hormonal and clinical evaluations were conducted during treatment and for a 6-month follow-up period. Serum 17 beta-estradiol levels were sharply suppressed. Luteinizing hormone was also decreased, whereas follicle-stimulating hormone, after an initial fall, gradually rose to pretreatment levels. Ovarian androgenic production was less inhibited, total testosterone being the only significantly suppressed hormone. There was a marked improvement of signs and symptoms of endometriosis and a 47.3% reduction of laparoscopic score. The results of this study suggest that goserelin depot provides a very good suppression of ovarian estrogen production and is highly effective in decreasing the symptoms of endometriosis with an acceptable compliance by the patient.
Venturini
P L
PL
Department of Gynecology and Obstetrics, University of Genoa, Italy.
Fasce
V
V
Costantini
S
S
Anserini
P
P
Cucuccio
S
S
de Cecco
L
L
D000328:Adult; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004702:Endocrine Glands / Q000187:drug effects*; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000502:physiology*; D017273:Goserelin; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D011388:Prolactin / Q000097:blood
D003692:Delayed-Action Preparations; D012739:Gonadal Steroid Hormones; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D011388:Prolactin; D002064:Buserelin